Biomax Informatics acquires data-mining business, eudaptics

30 September 2007

Aiming to enhance and broaden its technology and solution portfolio, Germany's Biomax Informatics AG has acquired the operative business of the Austrian data mining specialist eudaptics software gmbh.

This extends the Biomax offering with the "Viscovery" range of products. With its intuitive visual approach to data exploration, the Viscovery Suite ideally complements the knowledge management system offered by Biomax, the German firm says. This is especially important for areas such as biomarker identification and validation, toxicology and clinical research. Data mining products and solutions will be offered by Viscovery Software GmbH, a 100% subsidiary of Biomax.

Klaus Heumann, chief executive of Biomax, said: "with this acquisition, we can offer comprehensive solutions for the integrated analysis and interpretation of biological and clinical experimental data to our customers and thus strengthen our unique position in the market."

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK







Today's issue

Company Spotlight